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Chronic myeloid leukemia (CML) arises 
from a translocation event within a   
normal hematopoietic stem cell (HSC)   
that results in a protein fusion between   
the tyrosine kinase (TK) ABL and the 
breakpoint  cluster  region  (BCR)  en-
coded on chromosome 22. The result-
ing fusion gene encodes for BCR-ABL, 
a constitutively active kinase that drives 
disease  pathogenesis  by  increasing  the 
production  of  mature  and  immature 
myeloid  cells  (Rowley,  1973).  Over   
the last 10 yr, highly effective ABL TKIs 
have  been  developed  (Druker  et  al., 
1996). However, CML stem cells are   
inherently insensitive to these inhibitors, 
suggesting that CML is unlikely to be 
cured using TKIs alone and that com-
bination therapy with agents able to in-
duce apoptosis in CML stem cells in a 
selective  manner  will  be  required  for 
disease eradication (Graham et al., 2002; 
Bhatia et al., 2003; Mahon et al., 2010). 
With  growing  evidence  that  BCR-
ABL
+ CML stem cells are dependent 
on  several  key  survival  pathways,  this 
scenario may now be achievable, thus 
offering  the  possibility  of  developing 
novel therapeutic approaches.
BCL6: A key player in CML stem  
cell survival
Recent studies have added BCL6, a re-
pressive zinc finger TF, to a small team 
of players in the resistance of BCR-
ABL
+  stem  cells  to  TKI  treatment. 
Duy et al. (2011) generated a model 
for  Philadelphia
+  (Ph
+)  pre–B  cell 
acute lymphoblastic leukemia (ALL) and 
found that BCL6 is critical for the sur-
vival of stem cells. In Ph
+ ALL cells, 
BCL6  was  up-regulated  in  response   
to TKI, allowing the cells to survive 
treatment.  Furthermore,  BCR-ABL–
transformed  B  lymphoblasts  lacking 
BCL6 were not able to induce leuke-
mia in immunodeficient mice. Treat-
ment with the TKI imatinib was more 
effective in BCL6
/ BCR-ABL
+ ALL 
than  in  their  BCL6
+/+  counterparts, 
suggesting a protective role for BCL6 
in ALL stem cells treated with TKIs 
(Duy et al., 2011).
In  this  issue,  Hurtz  et  al.  demon-
strate that BCL6 up-regulation by TKI 
maintains  the  self-renewal  capacity  of   
CML-initiating cells by inducing Fork-
head box 3a (FOXO3a) signaling and by 
repressing Arf and p53. In CML, BCL6 
expression was repressed at the mRNA 
and  protein  level  in  a  BCR-ABL– 
dependent manner and was reactivated 
upon  treatment  with  TKI,  particu-
larly in primary CD34
+ and primitive 
CD34
+38
 cell subpopulations. Sensi-
tivity to imatinib was greatly increased 
in primitive mouse hematopoietic cells 
(Lin
Sca
1
+c-Kit
+;  LSK)  that  were   
retrovirally transduced with BCR-ABL 
but lacked BCL6, suggesting that BCL6 
was required for drug resistance in these 
cells. BCL6 was also required for main-
tenance of these cells, as BCL6
/ CML 
cells rapidly underwent apoptosis. Fur-
thermore,  a  dominant-negative  form 
of  BCL6  suppressed  leukemogenesis 
in vivo, and p53 was identified as a key 
transcriptional target of BCL6. In fact, 
p53 was required for the dominant- 
negative form of BCL6 to suppress col-
ony formation in vitro. Together, these 
data provide evidence that BCL6 func-
tions to protect CML stem cells from 
TKI treatment, at least in part, by sup-
pressing the Arf–p53 pathway.
First-string players in leukemic stem 
cell (LSC) survival
Several important factors have recently 
been investigated as potential key play-
ers  in  LSC  survival.  Some  of  these   
belong to the same signaling pathway 
as BCL6, whereas others are less di-
rectly involved; among the former are 
FOXO3a and phosphatase and tensin 
homologue (PTEN).
FOXO3a is a member of the FOXO   
TF family, which induces BCL6 ex-
pression  in  the  BCR-ABL
+  cell  line 
BV173  (Fernández  de  Mattos  et  al., 
2004). The studies by Duy et al. (2011) 
and Hurtz et al. (2011) both suggest 
that FOXO TFs are upstream inducers 
of BCL6, specifically FOXO4 in Ph
+ 
ALL  and  FOXO3a  in  CML.  The 
FOXO TFs, among other activators of 
BCL6,  are  negatively  regulated  by 
BCR-ABL  through  the  PI3K–AKT 
The resistance of leukemic stem cells in response to targeted therapies such 
as tyrosine kinase inhibitors (TKIs) relies on the cooperative activity of mul-
tiple signaling pathways and molecules, including TGF, AKT, and FOXO 
transcription factors (TFs). B cell lymphoma 6 (BCL6) is a transcriptional 
repressor whose translocation or mutation is associated with diffuse large 
BCL. New data now show that BCL6 is critical for the maintenance of leuke-
mias driven by the BCR-ABL translocation (Philadelphia chromosome), sug-
gesting that BCL6 is a novel, targetable member of the complex signaling 
pathways critical for leukemic stem cell survival.
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(2011) studies, conditional deletion of 
PTEN  abrogated  the  ability  of  Ph
+ 
ALL  and  CML  cells  to  up-regulate 
BCL6 in response to TKI treatment. 
Another group also showed a critical 
role for PTEN in both CML and Ph
+ 
ALL (Peng et al., 2010), as PTEN was 
down-regulated by BCR-ABL in LSCs, 
and its deletion led to accelerated leu-
kemia development. However, PTEN 
overexpression  delayed  the  develop-
ment of CML and Ph
+ ALL and pro-
longed survival of leukemic mice. It is 
likely that PTEN drives this survival 
effect  by  regulating  its  downstream 
protein AKT (Fig. 1).
Collectively,  these  studies  reveal 
several potentially targetable proteins   
in a single signaling pathway, including 
TGF-, AKT, and BCL6 (Fig. 1). Naka 
et  al.  (2010)  used  a  combination  of 
TGF-  inhibition  by  Ly364947  and 
TKI  treatment  and  found  that  CML 
was completely eradicated in the trans-
duction/transplantation  mouse  model. 
Duy  et  al.  (2011)  inactivated  BCL6 
with  the  retro-inverso  BCL6  peptide 
inhibitor RI-BPI, resulting in delayed 
progression  of  Ph
+  ALL.  In  addition, 
treatment with a combination of ima-
tinib and RI-BPI prevented acquisi-
tion of TKI resistance in the long term 
and potentiated the effect of TKI on 
refractory ALL cells. In the CML model, 
RI-BPI  targeted  primary  leukemic 
CD34
+ cells, including the more primi-
tive CD34
+38
 population, and inter-
fered with initiation of CML. Whereas 
RI-BPI alone did not significantly affect 
CML cell viability in vitro, it strongly 
enhanced the effect of imatinib. Sur-
vival of the K562 CML cell line was 
significantly inhibited and apoptosis was 
effectively  induced  when  mTOR,  a 
downstream target of AKT, was inhib-
ited by rapamycin (Peng et al., 2010). 
Rapamycin  also  blocked  ALL  leuke-
mogenesis induced by PTEN deletion 
in HSCs, suggesting that mTOR, like 
BCL6, is an important player in LSC 
survival (Lee et al., 2010). In keeping 
with a role for mTOR in LSC survival, 
the dual mTORC2/mTORC1 inhibitor 
OSI-027 has been shown to target pro-
genitors  from  CML  patients  (Carayol   
et al., 2010). Interestingly, the tumor 
The authors also suggested that TGF-, 
through  inhibition  of  AKT  activity, 
was  responsible  for  FOXO3a  activa-
tion. Nevertheless, no downstream ef-
fectors of FOXO3a were suggested to 
explain the FOXO3a-mediated main-
tenance of CML stem cells. Hurtz et al. 
(2011) provide a missing piece of this 
puzzle, and it is now possible to hypoth-
esize a more complete signaling cascade 
leading from TGF- through AKT to 
BCL6/p53 that maintains the survival 
of LSCs (Fig. 1).
Another player in the BCL6 signal-
ing  pathway  is  the  tumor  suppressor 
gene PTEN (Stambolic et al., 1998). 
PTEN  is  critical  in  adult  hemato-
poietic cells, and its deletion leads to 
transplantable ALL in association with 
induction of p16
Ink4a and p53 (Yilmaz 
et  al.,  2006;  Lee  et  al.,  2010).  The 
PI3K–AKT–FOXO pathway is nega-
tively regulated by PTEN, and in the 
Duy  et  al.  (2011)  and  Hurtz  et  al. 
pathway (Brunet et al., 1999). In Ph
+ 
cells,  these  TFs  are  normally  inactive 
and localized to the cytoplasm; how-
ever, TKI-mediated inhibition of BCR-
ABL leads to their activation and cell 
cycle  arrest  (Komatsu  et  al.,  2003). 
BCL6 up-regulation after TKI treat-
ment,  as  demonstrated  in  the  recent 
studies, provides one possible explana-
tion for why and how CML-initiating 
cells persist in patients despite long-term 
TKI  treatment.  It  has  been  shown   
that FOXO TFs are important for the 
maintenance  of  both  normal  and 
CML stem cells (Tothova et al., 2007; 
Naka et al., 2010). In the specific case 
of FOXO3a, a syngeneic murine trans-
duction/transplantation system that re-
produces CML-like disease was used to 
show that FOXO3a is essential for the 
maintenance of CML stem cells (Naka 
et  al.,  2010).  In  that  study,  deletion   
of FOXO3a abrogated the ability of 
CML  stem  cells  to  generate  disease. 
Figure 1.  PI3K, AKT, FOXO, and BCL6 are key players in Ph
+ stem cell survival. Ph
+ ALL and 
CML are dependent on signals emanating from BCR-ABL through the PI3K–AKT pathway that may be 
driven by TGF- via inhibition of AKT. BCL6 acts downstream of FOXO TFs and appears to represent a 
critical missing piece of the signaling pathway that leads to cancer stem cell survival. This signaling 
cascade offers potential for therapeutic modulation at various levels, including BCR-ABL inhibition 
by kinase inhibitors, TGF inhibition by Ly364947, and Bcl6 inhibition by RI-BPI.JEM Vol. 208, No. 11 2157
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Conclusions
Overall, the data strongly suggest that 
LSCs in both Ph
+ ALL and CML are 
dependent  on  signals  emanating  from 
the PI3K–AKT pathway that are at least 
partially mediated by TGF-. Several 
points in this signaling cascade offer   
the potential for therapeutic modulation, 
including TGF- itself. Because PTEN, 
FOXO3a, and BCL6 all belong to the 
same pathway, it is tempting to specu-
late that an effective TGF- inhibitor 
may be sufficient as a single agent; how-
ever, this might be associated with un-
acceptable  toxicity  to  normal  tissues 
that  depend  on  TGF-  for  survival. 
Therefore, the potential to inhibit the 
pathway at different points is extremely 
exciting.  For  these  reasons,  it  is  also 
wise  to  continue  to  investigate  other 
factors that have shown potential clini-
cal relevance in CML, such as Alox5, 
PP2A, and JAK2.
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